ARUNDHATHI JEYABALAN
Medical Practice in Pittsburgh, PA
License number
Pennsylvania MD070528L
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
Pittsburgh, PA 15217
Personal information
See more information about ARUNDHATHI JEYABALAN at radaris.comName
Address
Phone
1270 Fairstead Ln, Pittsburgh, PA 15217
Pittsburgh, PA
100 Denniston Ave, Pittsburgh, PA 15206
180 Denniston Ave, Pittsburgh, PA 15206
1270 Fairstead Ln, Pittsburgh, PA 15217
Organization information
See more information about ARUNDHATHI JEYABALAN at bizstanding.comArundhathi Jeyabalan MD
300 Halket St, Pittsburgh, PA 15213
Industry:
Obgyn
Phone:
(412) 641-4222 (Phone)
Description:
There are 9 doctors at this site. Surgery is performed at this site.
Arundhathi Jeyabalan
Magee-Womens Hospital - Arundhathi Jeyabalan MD
300 Halket St, Pittsburgh, PA 15213
Categories:
Gynecology & Obstetrics Physicians & Surgeons, Medical Research & Development
Site:
Phone:
(412) 641-6361 (Phone)
Products:
Arthritis & Rheumatology
Additional:
Margolls Rheumatology Associates - UPMC
Professional information
Arundhathi Jeyabalan, Pittsburgh PA
Specialties:
OB-GYN
Address:
300 Halket St, Pittsburgh, PA 15213
Education:
Doctor of Medicine
Board certifications:
American Board of Obstetrics and Gynecology Certification in Obstetrics & Gynecology, American Board of Obstetrics and Gynecology Sub-certificate in Maternal and Fetal Medicine (Obstetrics & Gynecology)
Arundhathi Jeyabalan, Pittsburgh PA
Work:
Magee-Womens Hospital of UPMC Health System
300 Halket St, Pittsburgh, PA 15213
300 Halket St, Pittsburgh, PA 15213
Dr. Arundhathi Jeyabalan, Pittsburgh PA - MD (Doctor of Medicine)
Specialties:
Maternal-Fetal Medicine
Address:
University Pittsburgh Physical
300 Halket St SUITE 0610, Pittsburgh 15213
(412) 641-6361 (Phone)
300 Halket St SUITE 0610, Pittsburgh 15213
(412) 641-6361 (Phone)
Certifications:
Fetal Medicine & Maternal Medicine, 2005, Obstetrics & Gynecology, 2011
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
University Pittsburgh Physical
300 Halket St SUITE 0610, Pittsburgh 15213
Magee-Womens Hospital of UPMC
300 Halket St, Pittsburgh 15213
UCSD Medical Center - Hillcrest
200 West Arbor Dr, San Diego 92103
300 Halket St SUITE 0610, Pittsburgh 15213
Magee-Womens Hospital of UPMC
300 Halket St, Pittsburgh 15213
UCSD Medical Center - Hillcrest
200 West Arbor Dr, San Diego 92103
Education:
Medical School
University Of Michigan Medical School
Graduated: 1994
University Ca San Diego Med Center
University Of Michigan Medical School
Graduated: 1994
University Ca San Diego Med Center
Prediction And Prevention Of Preeclampsia
US Patent:
2013030, Nov 14, 2013
Filed:
Jul 12, 2013
Appl. No.:
13/940530
Inventors:
Dennis Stewart - Los Gatos CA, US
Kirk P. Conrad - Gainsville FL, US
Arundhathi Jeyabalan - Pittsburgh PA, US
Marion Dahike - Basel, CH
Kirk P. Conrad - Gainsville FL, US
Arundhathi Jeyabalan - Pittsburgh PA, US
Marion Dahike - Basel, CH
International Classification:
A61K 38/22
US Classification:
514 127
Abstract:
The present disclosure relates to methods for assessing increased risk of preeclampsia in a pregnant woman. The methods described herein employ measuring relaxin levels, and optionally measuring C-reactive protein levels in a biological sample of a pregnant woman. The disclosure further encompasses methods of reducing risk of preeclampsia through administration of a pharmaceutical formulation of relaxin to a pregnant woman.
Prediction And Prevention Of Preeclampsia
US Patent:
2013001, Jan 10, 2013
Filed:
Feb 16, 2012
Appl. No.:
13/398215
Inventors:
Dennis Stewart - Los Gatos CA, US
Kirk P. Conrad - Gainesville FL, US
Arundhathi Jeyabalan - Pittsburgh PA, US
Marion Dahike - Basel, CH
Kirk P. Conrad - Gainesville FL, US
Arundhathi Jeyabalan - Pittsburgh PA, US
Marion Dahike - Basel, CH
International Classification:
A61K 38/22, C07K 16/26, A61P 43/00, G01N 33/566
US Classification:
514 127, 435 792, 53038824
Abstract:
The present disclosure relates to methods for assessing increased risk of preeclampsia in a pregnant woman. The methods described herein employ measuring relaxin levels, and optionally measuring C-reactive protein levels in a biological sample of a pregnant woman. The disclosure further encompasses methods of reducing the risk of preeclampsia and treating it, once it has occurred by administering a pharmaceutical formulation of relaxin to a pregnant woman.
Prediction And Prevention Of Preeclampsia
US Patent:
2011028, Nov 17, 2011
Filed:
Nov 24, 2009
Appl. No.:
13/129597
Inventors:
Dennis Stewart - LosGatos CA, US
Kirk P. Conrad - Gainesville FL, US
Arundhathi Jeyabalan - Pittsburgh PA, US
Kirk P. Conrad - Gainesville FL, US
Arundhathi Jeyabalan - Pittsburgh PA, US
Assignee:
University of Pittsburgh-Of the Comonwealth System - Pittsburgh PA
International Classification:
A61K 38/22, C07K 16/26, A61P 9/12, A61P 43/00, A61P 13/12, A61P 9/00, G01N 33/566, A61P 15/00
US Classification:
514 127, 435 792, 436501, 53038824
Abstract:
The present disclosure relates to methods for detecting an increased risk of preeclampsia, determining the presence of preeclampsia, reducing the likelihood that preeclampsia will develop and treating preeclampsia. It also provides methods of measuring relaxin levels in a biological sample of a pregnant woman.
Gene Expression Related To Preeclampsia
US Patent:
2011017, Jul 14, 2011
Filed:
Sep 16, 2009
Appl. No.:
13/119213
Inventors:
Kirk P. Conrad - Gainesville FL, US
Arundhathi Jeyabalan - Pittsburgh PA, US
Sandra Anne Founds - Wexford PA, US
William Allen Hogge - Pittsburgh PA, US
Arundhathi Jeyabalan - Pittsburgh PA, US
Sandra Anne Founds - Wexford PA, US
William Allen Hogge - Pittsburgh PA, US
Assignee:
University of Pittsburgh-Of the Commonwealth System of Higher Education - Pittsburgh PA
University of Florida Research Foundation, Inc. - Gainesville FL
University of Florida Research Foundation, Inc. - Gainesville FL
International Classification:
C12Q 1/68, G01N 33/53
US Classification:
435 611, 436501, 435 792
Abstract:
Gene expression patterns contemporaneous with early placental development in the first trimester of preeclamptic versus unaffected pregnancies have been obtained. Observation of differences in these gene expression patterns has allowed the identification of biomarkers that are useful in predicting and monitoring preeclampsia. These biomarkers are also useful in screening potential therapeutics for efficacy in the prevention or treatment of preeclampsia.